The Cardiovascular Safety of Celecoxib

• Silverstein FE , FaichG, GoldsteinJLet al.: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.JAMA, 284, 1247–1255 (2000).
   PubMed Web of Science ®Google Scholar
• Bombardier C , LaineL, ReicinAet al.: VIGOR study group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group.N. Engl. J. Med., 343, 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Bresalier RS , SandlerRS, QuanHet al.: Adenomatous Polyp PRevention On Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.N. Engl. J. Med., 352, 1092–1102 (2005).
   PubMed Web of Science ®Google Scholar
• Lipsky PE , BrooksP, CroffordLJet al.: Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.Arch. Intern. Med., 160, 913–920 (2000).
   PubMed Web of Science ®Google Scholar
• Whelton A : COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.J. Hypertens. 20(Suppl. 6), S31–S35 (2002).
   Google Scholar
• Solomon DH , SchneeweissS, LevinR, AvornJ: Relationship between COX-2 specific inhibitors and hypertension.Hypertension, 44, 140–145 (2004).
   PubMed Web of Science ®Google Scholar
• Wolfe F , ZhaoS, PettittD: Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal anti-inflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.J. Rheumatol., 31, 1035–1037 (2004).
   PubMed Web of Science ®Google Scholar
• Mamdani M , JuurlinkDN, LeeDSet al.: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.Lancet, 363, 1751–1756 (2004).
   PubMed Web of Science ®Google Scholar
• Hudson M , RichardH, PiloteL: Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.Br. Med. J., 330, 1370 (2005).
   PubMed Web of Science ®Google Scholar
• Bernatsky S , HudsonM, SuissaS: Antirheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis.Rheumatology, 44, 677–680 (2005).
   PubMed Web of Science ®Google Scholar
• Whelton A , FortJG, PumaJAet al.: SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.Am. J. Ther., 8, 85–95 (2001).
   PubMedGoogle Scholar
• Whelton A , WhiteWB, BelloAEet al.: SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis.Am. J. Cardiol., 90, 959–963 (2002).
   PubMed Web of Science ®Google Scholar
• Aw TJ , HaasSJ, LiewD, KrumH: Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.Arch. Intern. Med., 165, 490–496 (2005).
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Co-ordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA : Coxibs and cardiovascular disease.N. Engl. J. Med., 351, 1709–1711 (2004).
   PubMed Web of Science ®Google Scholar
• Libby P : Inflammation in atherosclerosis.Nature, 420, 868–874 (2002).
   PubMed Web of Science ®Google Scholar
• Schonbeck U , SukhovaGK, GraberPet al.: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions.Am. J. Pathol., 155, 1281–1291 (1999).
   PubMed Web of Science ®Google Scholar
• Ray WA , SteinCM, DaughertyJRet al.: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.Lancet, 360, 1071–1073 (2002).
   PubMed Web of Science ®Google Scholar
• Solomon DH , SchneeweissS, GlynnRJet al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation, 109, 2068–2073 (2004).
   PubMed Web of Science ®Google Scholar
• Levesque LE , BrophyJM, ZhangB: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.Ann. Intern. Med., 142, 481–489 (2005).
   PubMed Web of Science ®Google Scholar
• Graham DJ , CampenD, HuiRet al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.Lancet, 365, 475–481 (2005).
   PubMed Web of Science ®Google Scholar
• Johnsen SP , LarssonH, TaroneREet al.: Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.Arch. Intern. Med., 165, 978–984 (2005).
   PubMed Web of Science ®Google Scholar
• Hippisley -CoxJ, CouplandC: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.Br. Med. J., 330, 1366 (2005).
   PubMedGoogle Scholar
• Singh G , MithalA, TriadafilopoulosG: Both selective COX-2 inhibitors and non-selective NSAIDs increased the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class (Abstract OP0091).Annual European Congress of Rheumatology 2005, Vienna Austria, 8–11 June (2005).
   Google Scholar
• Mamdani M , RochonP, JuurlinkDNet al.: Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.Arch. Intern. Med., 163, 481–486 (2003).
   PubMed Web of Science ®Google Scholar
• Kimmel SE , BerlinJA, ReillyMet al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.Ann. Intern. Med., 142, 157–164 (2005).
   PubMed Web of Science ®Google Scholar
• White WB , FaichG, WheltonAet al.: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.Am. J. Cardiol., 89, 425–430 (2002).
   PubMed Web of Science ®Google Scholar
• White WB , FaichG, BorerJS, MakuchRW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.Am. J. Cardiol., 92, 411–418 (2003).
   PubMed Web of Science ®Google Scholar
• Moore RA , DerryS, MakinsonGT, McQuayHJ: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.Arthritis Res. Ther., 7, R644–R665 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon SD , McMurrayJJ, PfefferMAet al.: Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 352, 1071–1080 (2005).
   PubMed Web of Science ®Google Scholar
• Chenevard R , HurlimannD, BechirMet al.: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation, 107, 405–409 (2003).
   PubMed Web of Science ®Google Scholar
• Widlansky ME , PriceDT, GokceNet al.: Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.Hypertension, 42, 310–315 (2003).
   PubMed Web of Science ®Google Scholar
• Bogaty P , BrophyJM, NoelMet al.: Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.Circulation, 110, 934–939 (2004).
   PubMed Web of Science ®Google Scholar
• Monakier D , MatesM, KlutsteinMWet al.: Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes.Chest, 125, 1610–1615 (2004).
   PubMed Web of Science ®Google Scholar
• Title LM , GiddensK, McInerneyMM, McQueenMJ, NassarBA: Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease.J. Am. Coll. Cardiol., 42, 1747–1753 (2003).
   PubMed Web of Science ®Google Scholar
• Walter MF , JacobRF, DayCAet al.: Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.Atherosclerosis, 177, 235–243 (2004).
   PubMed Web of Science ®Google Scholar

Website

• Food and Drug Administration Centre for Drug Evaluation and Research. www.fda.gov/cder/drug/infopage/COX2/(Accessed May 2005)
   Google Scholar